Autonomix
About this raise
Autonomix, with a valuation of $70 million, is raising funds independently through Reg A+ crowdfunding. The company is developing a two-fold technology to detect malfunctioning neural signals and ablate nerves. Autonomix is opening up a world of possibilities in electrophysiology and working towards creating a simple procedure for pain management. The company is currently targeting pancreatic cancer pain and aims to target chronic pain, cardiovascular pain, and pulmonary diseases in the future. Dr. Robert Schwartz, Landy Roth, David Robins, and Dr. Robert Van Tassel founded Autonomix in 2014. The current crowdfunding campaign has a maximum target of $21.2 million. The campaign proceeds will be used for marketing, publishing, underwriting expenses, legal & accounting fees, and transfer agent.
Investment Overview
Invested : $6,200,610
Deal Terms
Total Commitments
- Platform
- DealMaker Securities
- Start Date
- 10/19/2023
- Close Date
- 01/29/2024
$750
$21,203,750
$750
Equity - Common
Growth Stage
RegA+
$5.00
$70,000,000
Company & Team
Company
- Year Founded
- 2014
- Industry
- Healthcare & Pharmaceuticals
- Tech Sector
- Distribution Model
- B2B
- Margin
- Medium
- Capital Intensity
- High
Upgrade to gain access
-
$12.50 /month
billed annually - Free portfolio tracking, data-driven ratings, AI analysis and reports
- Plan Includes:
- Everything in Free, plus
- Company specific
Kingscrowd ratings and analyst reports
- Deal explorer and side-by-side comparison
- Startup exit and failure tracking
- Startup market filters and historical industry data
- Advanced company search ( with ratings)
- Get Edge Annual
Edge
Ratings 
Company Funding & Growth
Funding history
- Total Prior Capital Raised
- $8,900,000
- VC Backed?
- No
| Close Date | Platform | Valuation | Total Raised | Security Type | Status | Reg Type |
|---|---|---|---|---|---|---|
| 01/29/2024 | DealMaker Securities | $70,000,000 | $6,200,610 | Equity - Common | Funded | RegA+ |